The Prostate Health Index: A new test for the detection of prostate cancer

Therapeutic Advances in Urology

Volumn 6, Issue 2, 2014, Pages 74-77

  Loeb, Stacy ^a   Catalona, William J ^b  

^a NEW YORK UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

free PSA; PHI; prognosis; prostate cancer; prostate health index; PSA; screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BLOOD EXAMINATION; CANCER EPIDEMIOLOGY; CANCER SCREENING; CANCER TEST; CLINICAL DECISION MAKING; DIGITAL RECTAL EXAMINATION; GLEASON SCORE; HIGH RISK POPULATION; HUMAN; MULTICENTER STUDY (TOPIC); NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NON INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HEALTH INDEX; PROSTATE VOLUME; REVIEW;

EID: 84896795915     PISSN: 17562872     EISSN: 17562880     Source Type: Journal    
DOI: 10.1177/1756287213513488     Document Type: Review

References (23)

1. American Cancer Society (ACS) (2013) Cancer facts & figures 2013 [online]. Atlanta, GA: American Cancer Society. Available at: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdf (accessed 1 August 2013).
2. Catalona W. Bartsch G. Rittenhouse H. Evans C. Linton H. Amirkhan A. (2003) Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J Urol 170: 2181–2185.
3. Catalona W. Partin A. Sanda M. Wei J. Klee G. Bangma C. (2011) A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol 185: 1650–1655.
4. Ferro M. Bruzzese D. Perdona S. Marino A. Mazzarella C. Perruolo G. (2013) Prostate Health Index (PHI) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2–10 ng/ml. PLoS One 8: e67687.
5. Lazzeri M. Haese A. Abrate A. de la Taille A. Redorta J. McNicholas T. (2013a) Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project. BJU Int 112: 313–321.
6. Lazzeri M. Haese A. de la Taille A. Palou Redorta J. McNicholas T. Lughezzani G. (2013b) Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2–10 ng/ml: a multicentric European study. Eur Urol 63: 986–994.
7. Le B. Griffin C. Loeb S. Carvalhal G. Kan D. Baumann N. (2010) [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study. J Urol 183: 1355–1359.
8. Lilja H. Christensson A. Dahlen U. Matikainen M. Nilsson O. Pettersson K. (1991) Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem 37: 1618–1625.
9. Loeb S. Carter H. Berndt S. Ricker W. Schaeffer E. (2012) Is repeat prostate biopsy associated with a greater risk of hospitalization? Data from SEER-Medicare. J Urol 189: 867–870.
10. Loeb S. Sokoll L. Broyles D. Bangma C. van Schaik R. Klee G. (2013) Prospective multicenter evaluation of the Beckman Coulter Prostate Health Index using WHO calibration. J Urol 189: 1702–1706.
11. Mikolajczyk S. Catalona W. Evans C. Linton H. Millar L. Marker K. (2004) Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem 50: 1017–1025.
12. Morgan V. Riches S. Thomas K. Vanas N. Parker C. Giles S. (2011) Diffusion-weighted magnetic resonance imaging for monitoring prostate cancer progression in patients managed by active surveillance. Br J Radiol 84: 31–37.
13. Murphy D. Costello T. Walsh P. Ahlering T. Cataolona W. Santor O. (2013) The Melbourne Consensus Statement on Prostate Cancer Testing [online], BJU International. Available at: http://www.bjuinternational.com/bjui-blog/the-melbourne-consensus-statement-on-prostate-cancer-testing/ (accessed 15 September 2013).
14. Ross A. Loeb S. Landis P. Partin A. Epstein J. Kettermann A. (2010) Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 28: 2810–2816.
15. Sanda M. Wei J. Broyles D. Shin S. Partin A. Klee G. (2013) Evaluation of the Prostate Health Index (PHI) for improving prostate cancer detection and identification of clinically significant prostate cancer in the 4 to 10 ng/mL PSA range. In: Proceedings of American Urological Association Annual Meeting, San Diego.
16. Scattoni V. Lazzeri M. Lughezzani G. De Luca S. Passera R. Bollito E. (2013) Head-to-head comparison of Prostate Health Index and urinary PCA3 for predicting cancer at initial or repeat niopsy. J Urol 190: 496–501.
17. Schroder F. Hugosson J. Roobol M. Tammela T. Ciatto S. Nelen V. (2012) Prostate-cancer mortality at 11 years of follow-up. New Engl J Med 366: 981–990.
18. Sokoll L. Sanda M. Feng Z. Kagan J. Mizrahi I. Broyles D. (2010) A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev 19: 1193–1200.
19. Sottile A. Ortega C. Berruti A. Mangioni M. Saponaro S. Polo A. (2012) A pilot study evaluating serum pro-prostate-specific antigen in patients with rising PSA following radical prostatectomy. Oncol Lett 3: 819–824.
20. Stenman U. Leinonen J. Alfthan H. Rannikko S. Tuhkanen K. Alfthan O. (1991) A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 51: 222–226.
21. Stephan C. Jung K. Semjonow A. Schulze-Forster K. Cammann H. Hu X. (2013) Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer. Clin Chem 59: 280–88.
22. Tosoian J. Loeb S. Feng Z. Isharwal S. Landis P. Elliot D. (2012) Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer. J Urol 188: 1131–1136.
23. Tosoian J. Loeb S. Kettermann A. Landis P. Elliot D. Epstein J. (2010) Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. J Urol 183: 534–538.